Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy

Asati, Vivek
Vaidya, Ankur

148,72 €(IVA inc.)

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1. The chapters are written by experts who actively work on the targets to help readers fully understand how they can be used in each specific case at clinical setting. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of novel cancer therapies based on molecular targets. Discusses recently discovered molecular targets for cancer therapy Brings updated literature of heterocyclic compounds, an important construction motif for the development of new anticancer drugs Encompasses comprehensive compilation of recently introduced anticancer drugs in the market, their health outcomes and Pharmacoeconomics INDICE: 1. Activin receptor-like kinase-2 (ALK2)2. Ataxia telangiectasia and Rad3-related protein(ATR)3. Breakpoint cluster region protein (BCR-AbL)4. Casein kinase (CK)5. c-Src kinase/Src-Abl6. Cyclin dependent kinase 4 and 67. Epidermal growth factor receptor (EGFR)8. Fyn-Blk-Lyn9. Insulin-like growth factor (IGFs)10. Mitotic kinesin spindle protein (KSP/Eg5 ATPase)11. p21-activated kinase 1 (PAK1)12. p38 mitogen-activated protein (MAP) kinase13. Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase14. Rearranged during Transfection (RET)15. Serine/threonine-protein kinase B-Raf16. Tubulin polymerization17. Tumor necrosis factor receptor associated protein 1 (TRAP1)18. Vascular Endothelial Growth Factor Receptors (VEGFR/PDGFR)

  • ISBN: 978-0-323-96121-9
  • Editorial: Academic Press
  • Encuadernacion: Rústica
  • Páginas: 500
  • Fecha Publicación: 01/07/2023
  • Nº Volúmenes: 1
  • Idioma: Inglés